Amicus Therapeutics, Inc.
FOLD
Classement en actions
#3689
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery,... Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
Prix de l'action
$14.49
Dernière synchronisation: 2026-04-27
Capitalisation boursière
$4.55B
Changement (1 jour)
0.00%
Changement (1 an)
71.68%
Pays
US
Échange Amicus Therapeutics, Inc. (FOLD)
Catégorie
Healthcare
Bénéfices pour Amicus Therapeutics, Inc. (FOLD)
Bénéfices en Dec 2025 TTM : $191.00K
Selon les derniers rapports financiers de Amicus Therapeutics, Inc., les bénéfices actuels de l'entreprise sont de $191.00K. En 2023, l'entreprise a réalisé un bénéfice de $-150.10M, une augmentation par rapport à celui de 2022 qui était de $-242.04M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Amicus Therapeutics, Inc. de 2003 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $191.00K | -100.66% |
| 2024 | $-28.76M | -80.84% |
| 2023 | $-150.10M | -37.98% |
| 2022 | $-242.04M | 0.20% |
| 2021 | $-241.55M | -11.92% |
| 2020 | $-274.25M | -22.94% |
| 2019 | $-355.91M | 1.95% |
| 2018 | $-349.09M | -22.27% |
| 2017 | $-449.12M | 120.39% |
| 2016 | $-203.78M | 54.24% |
| 2015 | $-132.12M | 88.63% |
| 2014 | $-70.04M | 10.92% |
| 2013 | $-63.15M | 21.36% |
| 2012 | $-52.03M | 8.30% |
| 2011 | $-48.04M | -14.33% |
| 2010 | $-56.08M | 753.89% |
| 2009 | $-6.57M | -83.31% |
| 2008 | $-39.36M | -4.40% |
| 2007 | $-41.17M | -11.17% |
| 2006 | $-46.34M | 125.15% |
| 2005 | $-20.58M | 0.00% |
| 2004 | 0.00 | -100.00% |
| 2003 | $-6.77M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| $5.27B | 2,761,627.75% |
US
|
|
| $-3.09B | -1,616,330.37% |
US
|
|
| $-4.02B | -2,102,820.66% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 1,021,182.77% |
NL
|
